Home > Boards > US Listed > Biotechs > Cel-Sci (CVM)

I do...

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
lightrock Member Profile
 
Followed By 19
Posts 3,218
Boards Moderated 0
Alias Born 10/15/16
160x600 placeholder
CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis Business Wire - 9/18/2020 9:00:00 AM
CEL-SCI Corporation Issues Letter to Shareholders Business Wire - 9/15/2020 9:15:00 AM
CEL-SCI Corporation to Present at H.C. Wainwright 22nd Annual Global Investment Conference Business Wire - 9/11/2020 9:00:00 AM
CEL-SCI Corporation Reports Third Quarter Fiscal 2020 Financial Results Business Wire - 8/11/2020 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 5:27:09 PM
CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine/Treatment Business Wire - 7/24/2020 8:30:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 7/13/2020 6:03:54 AM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 7/2/2020 5:39:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 10:37:54 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 10:36:13 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 10:34:55 AM
CEL-SCI Corporation Receives $10 Million Through Warrant Exercises Business Wire - 6/30/2020 8:30:00 AM
CEL-SCI to Present at H.C. Wainwright Virtual Fireside Chat Series Business Wire - 6/24/2020 10:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 5/26/2020 5:24:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2020 5:23:10 PM
CEL-SCI Corporation Reports Second Quarter Fiscal 2020 Financial Results Business Wire - 5/11/2020 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2020 5:04:18 PM
CEL-SCI’s Pivotal Phase 3 Study Has Reached the Required Number of Events to Evaluate Data for Multikine in Treatment of He... Business Wire - 5/4/2020 7:15:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 4/24/2020 5:50:15 PM
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head & Neck Cancer St... Business Wire - 4/23/2020 9:15:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 4/21/2020 6:01:11 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/20/2020 5:06:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/20/2020 5:03:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/20/2020 4:59:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/20/2020 4:56:22 PM
lightrock   Monday, 09/23/19 12:42:19 AM
Re: learning curve post# 25471
Post # of 33564 
I do...

For example, even if we are remarkably effective and 85% of all our test group is still alive, there is still 15% more better we can do.

It would be great to eliminate surgery, radiation, and especially mustard gas aka "chemo-therapy". ( if you look up the drugs for chemo-therapy seems all or most are derived from mustard gas )

There is a probability that if we "change the standard of care" it may only be by way of adding our method and substance to everything else.

It would be great to eliminate one or more of the existing treatment methods.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences